Skip to main content

Table 5 Surrogate subtyping by 3-marker scoring

From: PAM50 Breast Cancer Subtyping by RT-qPCR and Concordance with Standard Clinical Molecular Markers

 

Luminal A

Luminal B

HER2-E

Basal-like

ER+/PR+/HER2- (n = 471)

244 (52%)

170 (36%)

53 (11%)

4 (1%)

ESR1+/PGR+/ERBB2- (n = 397)

239 (60%)

127 (32%)

31 (8%)

0 (0%)

ER+/PR-/HER2- (n = 81)

12 (15%)

47 (58%)

19 (23%)

3 (4%)

ESR1+/PGR-/ERBB2- (n = 101)

15 (15%)

65 (64%)

18 (18%)

3 (3%)

ER-/PR-/HER2+ (n = 39)

0 (0%)

7 (18%)

30 (77%)

2 (5%)

ESR1-/PGR-/ERBB2+ (n = 51)

0 (0%)

6 (12%)

41 (80%)

4 (8%)

ER-/PR-/HER2- (n = 101)

4 (4%)

10 (10%)

30 (30%)

57 (56%)

ESR1-/PGR-/ERBB2- (n = 90)

0 (0%)

2 (2%)

28 (31%)

60 (67%)

ER+/PR+/HER2+ (n = 45)

2 (4%)

18 (40%)

25 (56%)

0 (0%)

ESR1+/PGR+/ERBB2+ (n = 80)

23 (29%)

33 (41%)

24 (30%

0 (0%)

ER+/PR-/HER2+ (n = 18)

0 (0%)

4 (22%)

14 (78%)

0 (0%)

ESR1+/PGR-/ERBB2+ (n = 53)

0 (0%)

28 (53%)

25 (47%)

0 (0%)

ER-/PR+/HER2- (n = 25)

14 (56%)

4 (16%)

3 (12%)

4 (16%)

ESR1-/PGR+/ERBB2- (n = 7)

0 (0%)

0 (0%)

4 (57%)

3 (43%)

ER-/PR+/HER2+ (n = 2)

1 (50%)

1 (50%)

0 (0%)

0 (0%)

ESR1-/PGR+/ERBB2+ (n = 3)

0 (0%)

0 (0%)

3 (100%)

0 (0%)